It is the most common mosquito borne disease which causes up to about 100-400 millions of cases per year globally, with  cause ~20000 deaths annually

The distribution of epidemic showed that outbreaks is happening all over the world. 

There 4 serotype of DENV, DENV-1, DENV-2, DENV-3 and DENV-4 . The co-circulation of multiple dengue serotypes in endemic area is common and increase the change of people developing severe manifestations such as DHF/DSS. 

There are available  two license vaccines, Dengvaxia® (CYD-TDV) and Denvax® (TAK003).  Dengvaxia,  only licensed for use in the prevention of all dengue serotypes in individuals aged 9–45 years in persons previously confirmed to have had dengue. And TAK-003 has the potential to be used for travelers to endemic areas regardless of serostatus,  but still under investigation. 

There is  any approved antiviral 
